不同剂量美托洛尔联合维格列汀治疗冠心病合并糖尿病的应用效果

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (614 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of different doses of Metoprolol combined with Vildagliptin in the treatment of coronary heart disease complicated with diabetes.Methods A total of 110 patients with coronary heart disease complicated with diabetes in Tengzhou Hospital of Traditional Chinese Medicine from May 2019 to February 2021 were selected as the research subjects,and were divided into study group and routine group according to random number table method,with 55 patients in each group.Both groups were treated with Vildagliptin combined with Metoprolol,the dosage of Metoprolol in the study group was 12.5 mg/time,twice a day.The dosage of Metoprolol in conventional group was 25 mg/time,twice a day.Treatment effect,cardiac function indexes (left ventricular ejection fraction[LVEF],left ventricular end-systolic diameter[LVESD],left ventricular end-diastolic diameter[LVEDD]),blood glucose indexes(fasting blood glucose[FPG],2 h postprandial blood glucose[2 h PG],glycosylated hemoglobin[HbA1c]),total incidence of adverse reactions,and serum inflammatory factors (Interleukin-6[IL-6],interleukin-8[IL-8],C-reactive protein[CRP]and tumor necrosis factor-α[TNF-α]) before and after treatment were compared between two groups.Results There was no significant difference in the total effective rate between two groups (P>0.05).The levels of FPG,2 h PG and HbA1c in two groups after treatment were lower than those before,and the levels of FPG,2 h PG and HbA1c in the study group were lower than those in the conventional group after treatment,the differences were statistically significant (P<0.05).After treatment,LVEF in the study group was higher than that in the conventional group,LVESD,LVEDD in the study group were lower than those in the conventional group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the study group was lower than that in the conventional group,the difference was statistically significant (P<0.05).After treatment,the levels of IL-6,IL-8,CRP and TNF-α in two groups were lower than those before,and the levels of IL-6,IL-8,CRP and TNF-α in study group were lower than those in control group,the differences were statistically significant (P<0.05).Conclusion When different doses of Metoprolol combined with Vildagliptin in the treatment of patients with coronary heart disease complicated with diabetes,the dose should be controlled at 12.5 mg/time,which can not only ensure the therapeutic effect,but also improve the control level of blood glucose in patients,help to reduce the incidence of adverse reactions in patients and improve the level of inflammatory factors in patients.

Key words： Vildagliptin Metoprolol Coronary heart disease Diabetes Heart function Blood glucose Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Liyu

Cite this article:

ZHOU Liyu. Effect of different doses of Metoprolol combined with Vildagliptin in the treatment of coronary heart disease complicated with diabetes[J]. 中国当代医药, 2022, 29(14): 58-62.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I14/58

[1]	李晓玲，陈燕燕，巩秋红，等.胰高糖素样肽-1 受体激动剂可降低超重/肥胖的2 型糖尿病合并冠心病患者的再发心血管风险[J].中华糖尿病杂志，2019，11（5）：341-346.
[2]	刘华，陈子平，刘奕然.利拉鲁肽联合二甲双胍治疗2 型糖尿病合并冠心病的临床效果及不良反应[J].中国医药科学，2021，11（10）：65-67.
[3]	朱长东，曾小兵，谢宝强，等.阿格列汀治疗2 型糖尿病合并冠心病的临床效果[J].中国当代医药，2020，27（11）：63-66.
[4]	陈伟.黄连温胆汤联合美托洛尔对2 型糖尿病合并心律失常病人血清脂联素，肿瘤坏死因子-α 水平及心率变异性的影响[J].中西医结合心脑血管病杂志，2019，17（15）：2312-2315.
[5]	蔡旭阳，金朝辉，吴斌，等.曲美他嗪联合美托洛尔治疗冠心病伴心力衰竭效果和安全性的系统评价[J].中国医药导报，2019，16（7）：142-145.
[6]	World Health Organization.Diabetes Mellitus：report of a WHO study group[J].WHO，1985，727（1）：1-113.
[7]	颜红兵.临床冠心病诊断与治疗指南[M].北京：人民卫生出版社：2010.
[8]	张洪波，焦鹏程，尹湘莎，等.北京市东城区社区糖尿病患者冠心病患病状况及影响因素研究[J].中国全科医学，2020，23（25）：3234-3240.
[9]	吉训恋，陆士娟.脑心通胶囊联合美托洛尔对老年缺血性心肌病心力衰竭患者的临床疗效[J].中成药，2020，42（1）：254-256.
[10]	王柳，郑颖，林德洪，等.美托洛尔片联合曲美他嗪片治疗老年冠心病心力衰竭患者的临床研究[J].中国临床药理学杂志，2020，36（15）：2175-2177.
[11]	张红梅.曲美他嗪联合美托洛尔治疗冠心病心力衰竭的疗效及对心功能的影响[J].医药论坛杂志，2018，39（2）：163-164.
[12]	王淼.不同剂量美托洛尔治疗糖尿病合并冠心病患者的效果对比[J].中西医结合心血管病杂志，2016，4（6）：39-40.
[13]	王小芳，杨露露，李文书，等.西格列汀对糖尿病患者心脏舒张功能和心肌纤维化的影响[J].临床心血管病杂志，2018，34（4）：376-380.
[14]	纪立农.大变革-基于心血管保护的糖尿病药物治疗模式展望[J].中国糖尿病杂志，2017，25（11）：961-969.
[15]	甄莉景，刘士霞，陈宝虎，等.维格列汀联合美托洛尔对2 型糖尿病合并冠心病患者血清APN、Hcy 及IMT 水平的影响[J].临床合理用药杂志，2016，9（8）：26-27.
[16]	陈宝虎，崔慧芳.维格列汀联合美托洛尔对2 型糖尿病合并冠心病的疗效及心功能的影响[J].解放军预防医学杂志，2017，35（8）：919-921.
[17]	李春杏，纪立伟，刘桦.卡维地洛与美托洛尔对糖脂代谢影响的系统性评价[J].中国循证心血管医学杂志，2020，12（2）：135-142